MARKET WIRETradingView • 19h ago
Dyadic International, Inc. Estimates – NASDAQ:DYAITradingView report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.
Why DYAI Stock surged +5.32% Today — RQD Quant Desk Flash
$0.38 +5.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.38
Dyadic International Inc. (DYAI) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $15.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on DYAI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is DYAI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Dyadic International Inc. (NASDAQ: DYAI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.38 (+5.32% 1D, market cap $15.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DYAI ranks #775 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does DYAI compare to ABOS and SCLX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DYAI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 24.9%, and ROIC of -35.0%. By comparison, ABOS (Acumen Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M) and SCLX (Scilex Holding Company) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $15.7M). Among the 5-stock peer group, DYAI leads on earnings multiple (N/A) while DYAI leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for DYAI?
▼
Per DYAI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001213809), Dyadic International Inc. generated $3.1M in revenue (-11.6% YoY), -$7.4M in net income, and -$5.7M in free cash flow against $9.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.38 (+0.77%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-13.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DYAI)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
🔍 WHY DYAI SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (32% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (23% of score)
FRED Regime × Technicals: 3% of 52W Range • RSI-14 at 40.8 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$0.43-9.3% Next Q
39
Q2 (-2Q)Grade E$0.39+0% Next Q
36
Q3 (-1Q)Grade E$0.39-2.6% Next Q
34
CurrentGrade E$0.38-9.4% Hist 90D α
31
Trajectory: E (39) → E (31)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a DYAI Turnaround Squeeze
While DYAI currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.45) and Max Pain ($0.40) forces dealer call-delta covering toward $1.68.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $DYAI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “DYAI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why DYAI Stock surged +5.32% Today — RQD Quant Desk Flash
Dyadic International Inc. (DYAI) surged +5.32% to $0.38, trading at 3% of its 52-week range ($0.34 – $1.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 3% of its 52-week range ($0.34 – $1.6) with RSI-14 at 40.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.38 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 24.9% gross margin and $0 annual free cash flow.
Live DYAI Headlines & Catalysts
MARKET WIREYahoo Finance • 22h ago
Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026Yahoo Finance report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A passive stake tops 5% at Dyadic International (DYAI), with voting power shared.Stock Titan report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREKalkine • 1d ago
What Explains the 7.87% Pre-Market Rise in Dyadic International (NASDAQ:DYAI) on October 29?Kalkine report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
How One Biotech Stock Is Trying To Reduce A Big Hidden CostYahoo Finance report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Dyadic International (DYAI) Slips 2.69% to $0.41 as Shares Sit Between Key Levels - Ichimoku Kumo Twisthttps://www.siam.in/ report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
Nasdaq sets two tests for Dyadic International stockad-hoc-news.de report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
Most Active Stocks Today: U.S. MarketTradingKey report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 18d ago
Dyadic International 13G Filing Shows Empery Asset Management Reports 8.35% Stake In Co. As Of Sept. 30https://www.sec.gov/Archives/edgar/data/1213809/000091957426006982/xslSCHEDULE_13G_X02/primary_doc.xml
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DYAI)
- ✓Walkthrough of DYAI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
DYAI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -49.33%▲ RESISTANCE BREAKOUT
2026-11-03O $0.36H $0.38L $0.36C $0.38VOL 113.5K
RES: $0.37SUP: $0.20SMA50: $0.45SMA200: $0.76
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
DYAI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -11.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on DYAI today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for DYAI. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for DYAI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DYAI)
Health Care Rank #775 of 1016
⚔️ ABOS vs DYAI Full Matrix →
1. Head-to-Head Health Care Peer Comparison (DYAI vs. ABOS, SCLX, PLUR, JSPR)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Dyadic International Inc. (DYAI) ranks #775 by composite RQD confidence (31/100, grade E) and #854 by equity capitalization ($15.2M). Within this direct 5-issuer industry benchmark cohort, DYAI leads on earnings valuation at N/A trailing P/E, while DYAI leads on capital efficiency and profitability with -35.0% ROIC and 24.9% gross margin. SCLX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with DYAI at 31/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| DYAI
ACTIVE
Dyadic International Inc. | E | 31/100 | — | 24.9% | -35.0% | +5.32% | $15.2M | Benchmark Subject |
| ABOS Acumen Pharmaceuticals Inc. | E | 33/100 | — | — | -35.0% | -90.82% | $15.2M | /abos-vs-dyai → |
| SCLX Scilex Holding Company | D- | 40/100 | — | 96.0% | -35.0% | -10.19% | $15.7M | /sclx-vs-dyai → |
| PLUR Pluri Inc. | E | 34/100 | — | 49.0% | -35.0% | +3.33% | $16.7M | /plur-vs-dyai → |
| JSPR Jasper Therapeutics Inc. | D- | 36/100 | — | — | -35.0% | -2.22% | $17.3M | /jspr-vs-dyai → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001213809In its most recent audited fiscal period (FY2025, filed 2025-12-31), Dyadic International Inc. (DYAI) reported GAAP revenue of $3.1M (-11.6% vs. FY2024 revenue of $3.5M , and +6.6% cumulative change since FY2023) , GAAP net income of -$7.4M, operating cash flow of -$5.7M, and free cash flow of -$5.7M (-43.5% YoY). On the balance sheet, DYAI closed FY2025 with $9.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $3.1M | -$7.4M | -$5.7M | -$5.7M | $9.9M | — |
| FY2024 (FY) | 2024-12-31 | $3.5M | -$5.8M | -$4.0M | -$4.0M | $9.9M | — |
| FY2023 (FY) | 2023-12-31 | $2.9M | -$6.8M | -$6.7M | -$6.7M | — | — |
3. DYAI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs DYAI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Dyadic International Inc. (NASDAQ: DYAI) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $0.38 (+5.32% 1D, market cap $15.2M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DYAI ranks #775 in composite RQD confidence.
How does DYAI compare to ABOS and SCLX in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DYAI carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 24.9%, and ROIC of -35.0%. By comparison, ABOS (Acumen Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $15.2M) and SCLX (Scilex Holding Company) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $15.7M). Among the 5-stock peer group, DYAI leads on earnings multiple (N/A) while DYAI leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for DYAI?
Per DYAI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001213809), Dyadic International Inc. generated $3.1M in revenue (-11.6% YoY), -$7.4M in net income, and -$5.7M in free cash flow against $9.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is DYAI trading relative to its 50-day, 200-day, and 52-week technical levels?
DYAI last traded at $0.38 (+5.32% on volume of 113,466 shares), positioning the stock -15.56% below its 50-day simple moving average ($0.45) and -50.00% below its 200-day simple moving average ($0.76). Across its 52-week range of $0.34 to $1.60, DYAI sits at the 3.2% percentile with a 14-day RSI of 40.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.43).
ROARABLE RATING BRIEF • RQD 31/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
DYAI — Dyadic International Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:50:45Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, DYAI scores 31 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the fundamental cash engine scores 6 of 20 (ROIC -35%; FCF yield 0%), indicating that the business is not currently generating cash returns relative to capital. The whale 13F flow pillar scores 10 of 20 for institutional accumulation and options positioning, the strongest of the five but still below midpoint. Insider conviction scores 3 of 20 based on SEC Form 4 and Congressional PTR cluster flow, the weakest signal in the rating. Macro regime fit scores 7 of 20 (Beta 1.0; sector sensitivity). The forensic balance sheet pillar scores 5 of 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5), signaling elevated distress and weak accounting-quality markers. For a prospective investor, the upside case rests mainly on institutional positioning rather than operating performance, while valuation tradeoffs are dominated by negative margins and the absence of free-cash-flow yield. The rating itself is an analytical classification and not personalized advice.
Business
Dyadic International Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the market data, gross margin is 24.9%, which indicates the company retains a portion of revenue after direct costs. Revenue is reported in the SEC financials at $3.1M for FY 2025. Customer base and specific product or service detail are —
Recent Catalysts & News Wire Analysis
Per the recent news data, DYAI-related items include a headline announcing that Dyadic will report Q3 2026 financial results and host a conference call on Thursday November 12, 2026. A passive stake exceeding 5% in the company, with voting power shared, is also reported. A Kalkine item references a 7.87% pre-market rise on October 29. Another headline references the price slipping 2.69% to $0.41 amid Ichimoku indicators. All items are marked as YELLOW light and MARKET WIRE impact. Per the Butterfly Supply-Chain Graph, no proprietary signals are present. Risk watch items include the sub-$1 share price and the market-data change of -8.4%.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, supply chain is NONE and no butterfly links are recorded. Upstream and downstream dependencies: — Sector correlations beyond the Health Care classification: — Second-order bottlenecks: —
Analyst View & Smart Money Ownership
Analyst data: — Holders data: — The only ownership-related signal is the news report of a passive stake above 5% noted in the news wire, with the rating's whale 13F flow pillar scoring 10 of 20.
Open Questions
- What is the composition of the $3.1M FY 2025 revenue, and is it recurring?
- What are the debt obligations, since the debt field is reported as N/A across periods?
- What is the cash runway given $4.6M cash against FY 2025 FCF of $-5.7M?
- Who holds the passive stake above 5%, and what is the voting arrangement?
- What are the EPS and P/E values, which are not reported in the source data?
DYAI Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Dyadic International Inc. (DYAI) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingView • 19h ago
Dyadic International, Inc. Estimates – NASDAQ:DYAI TradingView report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 22h ago
Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026 Yahoo Finance report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A passive stake tops 5% at Dyadic International (DYAI), with voting power shared. Stock Titan report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Kalkine • 1d ago
What Explains the 7.87% Pre-Market Rise in Dyadic International (NASDAQ:DYAI) on October 29? Kalkine report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
How One Biotech Stock Is Trying To Reduce A Big Hidden Cost Yahoo Finance report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Dyadic International (DYAI) Slips 2.69% to $0.41 as Shares Sit Between Key Levels - Ichimoku Kumo Twist https://www.siam.in/ report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
Nasdaq sets two tests for Dyadic International stock ad-hoc-news.de report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
Most Active Stocks Today: U.S. Market TradingKey report covering Dyadic International Inc. (DYAI) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
DYAI Bull vs. Bear Conversation Board — What's Your Call at $0.38?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON DYAI 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $0.32 (-11.1%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is DYAI (E • RQD 31/100) a Buy at $0.36?
Welcome to the DYAI (Dyadic International Inc.) Roar Pit. Current RQD Composite is 31/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $0.30 (-16.7%)
Spot @ $0.36 Pump the brakes on DYAI — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on DYAI, but look at what you are paying: current EV/EBITDA multiples with 24.9% gross margins. Unless Dyadic International Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MI MidwestValue Verified K Arena Trader 🐂 BULLISH
🎯 Target: $0.45 (+25.0%)
Spot @ $0.36 DYAI cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on DYAI, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $0.36 (52-wk range $0.34 - $1.60), any beat on forward guidance forces shorts and underweight funds to chase.